Top Story Today
A Disease That Turns Muscle Into Bone Finally Has a Drug. It Took a Decade and a Safety Crisis to Get Here.
Regeneron's Pasatru (garetosmab) has won FDA approval for fibrodysplasia ossificans progressiva, a disease that progressively turns soft tissue into bone. In the Phase 3 OPTIMA trial, the drug slashed new bone formation volume by over 99% at 56 weeks compared to placebo. That's a staggering number for a condition where the prior standard of care was essentially "avoid falling down." The road here was brutal: five patient deaths during an earlier extension study nearly killed the program, and Regeneron pulled the drug from its filing plans in 2021 before deciding to try again.
Why it matters: Beyond 834 confirmed FOP patients worldwide, this approval validates activin A blockade as a viable strategy against abnormal bone formation, a problem that also plagues hip replacement recovery, spinal cord injuries, and battlefield trauma. The smallest patient populations sometimes produce the biggest proof-of-concept wins.
Read more →FDA and Regulatory
Trump's FDA Pick Has Never Run a Regulatory Agency. That's the Point.
President Trump tapped White House policy adviser Dr. Heidi Overton to lead the FDA, choosing loyalty over regulatory experience at the most scientifically complex moment in the agency's history. Raymond James analyst Chris Meekins called the pick "extremely troublesome," while Republican Sen. Bill Cassidy has already raised concerns. The inbox waiting for her includes mRNA vaccine decisions, gene therapy resubmissions, and an agency still reeling from staff cuts.
Read more →The FDA Just Lowered the Drawbridge on Cancer Diagnostics
The FDA is reclassifying key oncology diagnostics from Class III to Class II, swapping the expensive PMA approval pathway for the faster, cheaper 510(k) route. The move covers ISH companion diagnostic tests (effective September 16) and proposes the same for blue-light cystoscopy systems used to detect bladder cancer. Incumbents like Photocure and Abbott's Vysis brand could soon face a wave of new competitors.
Read more →A Boy Died in a Gene Therapy Trial a Year Ago. We Just Found Out.
A child in HuidaGene's CRISPR-based Duchenne muscular dystrophy trial died from a severe immune reaction in August 2025. The company didn't publicly acknowledge the death until August 2026, and only after months of journalist investigation. The case spotlights systemic transparency gaps in China's investigator-initiated trial framework and raises urgent questions about safety communication across the gene therapy field.
Read more →Deals and M&A
Jazz Bet $1.3 Billion on an Epilepsy Channel Nobody's Cracked
Jazz Pharmaceuticals is paying up to $1.32 billion ($820 million upfront) for Actio Biosciences and its KCNT1 epilepsy inhibitor, a Phase 1b/2 drug targeting a rare childhood seizure disorder with zero approved treatments. The deal deepens Jazz's precision epilepsy strategy beyond Epidiolex and follows its 2025 Saniona licensing deal. Only about 3,000 patients are diagnosed worldwide, but orphan drug economics and no competition make the math work.
Read more →BioMarin Pays $275M to Replace Needles With a Pill for Rare Bone Disease
BioMarin acquired Alesta Therapeutics for $275 million upfront (up to $490 million total) to get ALE1, a Phase 1/2a oral small molecule for hypophosphatasia. The drug targets excess pyrophosphate through a novel mechanism, potentially replacing the only current option: lifelong injections of Strensiq. No patient efficacy data exists yet; initial results are expected later this year.
Read more →The Organ You Forgot About Just Landed a $260M Deal
Tolerance Bio licensed efineptakin alfa, a long-acting IL-7 fusion protein, from South Korea's NeoImmuneTech for up to $260 million in milestones. The bet: reviving the thymus (your immune system's shrinking boot camp) could reset immune tolerance for autoimmune disease and transplant rejection. The drug has been tested in multiple clinical studies, but never specifically for thymic restoration.
Read more →J&J Returned a $245M CAR-T Asset. The Tiny Biotech That Made It Just Got FDA Clearance.
After J&J handed back global rights to prizlon-cel in July 2026, AbelZeta promptly scored FDA IND clearance to start U.S. trials. The early Chinese data backing the drug is striking: a 91.5% overall response rate and 85.1% complete response rate in 48 lymphoma patients, with promising long-term progression-free survival. Now AbelZeta must prove those results translate in American patients.
Read more →Science and Discovery
An LSD Pill Just Posted the First Clean Phase 3 Win for Any Psychedelic
Definium Therapeutics' DT120, a pharmaceutical-grade LSD formulation, beat placebo by 5.4 points on the gold-standard anxiety scale (p<0.0001) in a 214-patient Phase 3 trial for generalized anxiety disorder. Onset was observed as early as Day 2, with benefits lasting the full 12 weeks. A second pivotal trial reads out in 2027; if it confirms these results, an FDA filing could follow.
Read more →Harvard Kept Mini-Brains Alive for Five Years. They Tracked Time Like a Clock.
A Harvard team kept human brain organoids alive for over five years, nearly tripling the previous record of 694 days. Published in Nature, the study showed these peppercorn-sized tissue clumps matured along a human developmental timeline, with cells resuming development at the right stage even after being paused. The advance could transform research into slow-moving brain diseases like Alzheimer's and Parkinson's.
Read more →